Literature DB >> 11294675

Survival of patients with AIDS, after diagnosis of Pneumocystis carinii pneumonia, in the United States.

M S Dworkin1, D L Hanson, T R Navin.   

Abstract

To examine survival after diagnosis of Pneumocystis carinii pneumonia (PCP) and factors associated with early death (during the month of or the month after diagnosis of PCP), data were analyzed from the Adult and Adolescent Spectrum HIV Disease project. Among 4412 patients with 5222 episodes of PCP during follow-up (1992-1998), survival at >1 month after diagnosis was 82%, and survival at > or =12 months after diagnosis was 47%; 12-month survival increased from 40% in 1992-1993 to 63% in 1996-1998. By multiple logistic regression analysis, early death was associated with history of PCP (odds ratio [OR], 1.4), age 45-59 years (OR, 1.9) or > or =60 years (OR, 3.7), and CD4 cell count of 0-24 cells/microL (< or =5 months before PCP; OR, 1.8) or 25-49 cells/microL (OR, 1.4) (P<.05). Concurrent prescription of combination antiretroviral therapy (OR, 0.2) and other antiretroviral therapy (OR, 0.4) was associated with surviving the early period. This study shows improved survival after diagnosis of PCP in recent years, despite emergence of antibiotic-resistant mutant P. carinii strains.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11294675     DOI: 10.1086/319866

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  The pulmonary physician in critical care * Illustrative case 5: HIV associated pneumonia.

Authors:  R J Boyton; D M Mitchell; O M Kon
Journal:  Thorax       Date:  2003-08       Impact factor: 9.139

2.  Eosinophils Contribute to Early Clearance of Pneumocystis murina Infection.

Authors:  Taylor Eddens; Waleed Elsegeiny; Michael P Nelson; William Horne; Brian T Campfield; Chad Steele; Jay K Kolls
Journal:  J Immunol       Date:  2015-05-20       Impact factor: 5.422

3.  Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006.

Authors:  Peter D Walzer; Hannah E R Evans; Andrew J Copas; Simon G Edwards; Alison D Grant; Robert F Miller
Journal:  Clin Infect Dis       Date:  2008-02-15       Impact factor: 9.079

4.  Clinical significance and phylogenetic relationship of novel Australian Pneumocystis jirovecii genotypes.

Authors:  Sebastiaan J van Hal; Felix Gilgado; Tom Doyle; Joel Barratt; Damien Stark; Wieland Meyer; Jock Harkness
Journal:  J Clin Microbiol       Date:  2009-04-15       Impact factor: 5.948

Review 5.  Epidemiology and long-term survival in HIV-infected patients with Pneumocystis jirovecii pneumonia in the HAART era: experience in a university hospital and review of the literature.

Authors:  Cristina López-Sánchez; Vicenç Falcó; Joaquin Burgos; Jordi Navarro; María Teresa Martín; Adrià Curran; Lucía Miguel; Inma Ocaña; Esteve Ribera; Manel Crespo; Benito Almirante
Journal:  Medicine (Baltimore)       Date:  2015-03       Impact factor: 1.889

6.  Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study.

Authors:  Dina Creemers-Schild; Frank P Kroon; Ed J Kuijper; Mark G J de Boer
Journal:  Infection       Date:  2015-10-15       Impact factor: 3.553

7.  Lymphocyte subset analysis to evaluate the prognosis of HIV-negative patients with pneumocystis pneumonia.

Authors:  Fan Jin; Jing Xie; Huan-Ling Wang
Journal:  BMC Infect Dis       Date:  2021-05-14       Impact factor: 3.090

8.  Risk factors of in-hospital mortality in patients with pneumocystis pneumonia diagnosed by metagenomics next-generation sequencing.

Authors:  Jun-Na Hou; Heng-Dao Liu; Qiu-Yue Tan; Feng-An Cao; Shi-Lei Wang; Meng-Ying Yao; Yang-Chao Zhao
Journal:  Front Cell Infect Microbiol       Date:  2022-09-26       Impact factor: 6.073

9.  Improving the representativeness of behavioral and clinical surveillance for persons with HIV in the United States: the rationale for developing a population-based approach.

Authors:  A D McNaghten; Mitchell I Wolfe; Ida Onorato; Allyn K Nakashima; Ronald O Valdiserri; Eve Mokotoff; Raul A Romaguera; Alice Kroliczak; Robert S Janssen; Patrick S Sullivan
Journal:  PLoS One       Date:  2007-06-20       Impact factor: 3.240

10.  Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years.

Authors:  Julius J Schmidt; Catherina Lueck; Stefan Ziesing; Matthias Stoll; Hermann Haller; Jens Gottlieb; Matthias Eder; Tobias Welte; Marius M Hoeper; André Scherag; Sascha David
Journal:  Crit Care       Date:  2018-11-19       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.